Bayer’s Yasmin and 10 other oral contraceptive pills (OCP) must contain serious warning labels because they increase women’s risk of blood clots, US health regulators say. In its latest statement, the Food and drug Administration (FDA) highlighted that OCPs containing drospirenone, a synthetic version of the hormone progesterone, should carry new labels warning about their potential fatal risk. Observational studies showed that the pills triple women’s risk for blood clots, the FDA noted in its medication safety alert. The Administration’s latest decision about new labels follows recommendations made in December by its appointed panel that suggested using revised warning labels for a number of drospirenone-containing contraceptives. The advisers highlighted that benefits of the class of OCPs still outweigh the risks and suggested a label change to better reflect the potential for blood clots. The FDA suggested women talk to their doctors before deciding on an oral contraceptive. “To put the risk of developing a blood clot from a birth control pill into perspective: The risk of blood clots is higher when using any birth control pills than not using them, but still remains lower than the risk of developing blood clots in pregnancy and in the postpartum period,” the FDA said.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor